“An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects”
The purpose of this trial is to determine the absorption, metabolism, and excretion (AME) of [14C] tavapadon.
Drug - Tavapadon tablet
Participants will receive multiple dose titration of Tavapadon (0.25 mg once daily [QD] on Days 1 to 3, 0.5 mg QD on Days 4 to 6, 1.0 mg QD on Days 7 to 9, 1.5 mg QD on Days 10 to 12, and 2.5 mg QD on Days 13 to 15)
Drug - Tavapadon [14C] suspension
Following 15-Day multiple dose titration of Tavapadon, participants will receive a single oral dose of Tavapadon 2.5 mg containing approximately 100 Î¼Ci of [14C] Tavapadon on Day 16
An Open-label Trial to Evaluate the Absorption, Metabolism, and Excretion of a Single Dose of [14C]-Tavapadon in Healthy Adult Male Subjects at Steady State